Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model

• Published in: Molecular therapy Vol. 25; no. 4; pp. 892 - 903
• Main Authors: Gray-Edwards, Heather L., Regier, Debra S., Shirley, Jamie L., Randle, Ashley N., Salibi, Nouha, Thomas, Sarah E., Latour, Yvonne L., Johnston, Jean, Golas, Gretchen, Maguire, Annie S., Taylor, Amanda R., Sorjonen, Donald C., McCurdy, Victoria J., Christopherson, Peter W., Bradbury, Allison M., Beyers, Ronald J., Johnson, Aime K., Brunson, Brandon L., Cox, Nancy R., Baker, Henry J., Denney, Thomas S., Sena-Esteves, Miguel, Tifft, Cynthia J., Martin, Douglas R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 05.04.2017; Elsevier Limited; American Society of Gene & Cell Therapy
• Subjects: AAV gene therapy; Age; Animals; Biomarkers; Biomarkers - blood; Biomarkers - cerebrospinal fluid; Biomarkers - urine; Brain architecture; Cats; Cerebrospinal fluid; Clinical trials; Demyelination; Dependovirus - classification; Dependovirus - genetics; Disease; Disease Models, Animal; EEG; Electroencephalography; Epilepsy; Gangliosidosis; Gangliosidosis, GM1 - genetics; Gangliosidosis, GM1 - metabolism; Gangliosidosis, GM1 - mortality; Gangliosidosis, GM1 - therapy; Gene therapy; Genetic Therapy - methods; Genetic Vectors - administration & dosage; Genetic Vectors - genetics; Humans; Hypocalcemia - metabolism; lysosomal storage disorders; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Metabolites; neurodegeneration; Neurodegenerative diseases; Original; Patients; Preservation; Rhythms; Software; Studies; Treatment Outcome; Urine; neurodegeneration; AAV gene therapy; gangliosidosis; lysosomal storage disorders
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1016/j.ymthe.2017.01.009

GM1 gangliosidosis is a fatal neurodegenerative disease that affects individuals of all ages. Favorable outcomes using adeno-associated viral (AAV) gene therapy in GM1 mice and cats have prompted consideration of human clinical trials, yet there remains a paucity of objective biomarkers to track disease status. We developed a panel of biomarkers using blood, urine, cerebrospinal fluid (CSF), electrodiagnostics, 7 T MRI, and magnetic resonance spectroscopy in GM1 cats—either untreated or AAV treated for more than 5 years—and compared them to markers in human GM1 patients where possible. Significant alterations were noted in CSF and blood of GM1 humans and cats, with partial or full normalization after gene therapy in cats. Gene therapy improved the rhythmic slowing of electroencephalograms (EEGs) in GM1 cats, a phenomenon present also in GM1 patients, but nonetheless the epileptiform activity persisted. After gene therapy, MR-based analyses revealed remarkable preservation of brain architecture and correction of brain metabolites associated with microgliosis, neuroaxonal loss, and demyelination. Therapeutic benefit of AAV gene therapy in GM1 cats, many of which maintain near-normal function >5 years post-treatment, supports the strong consideration of human clinical trials, for which the biomarkers described herein will be essential for outcome assessment. GM1 gangliosidosis is a fatal, untreatable neurodegenerative disease of children and adults. Gray-Edwards and colleagues demonstrate >5-year survival in AAV-treated GM1 cats and describe novel minimally invasive biomarkers for use in clinical trials. Analyses of blood, cerebrospinal fluid, electroencephalography, MRI, and MRS are included from GM1 cats and human patients.